276 related articles for article (PubMed ID: 36860848)
1. Exploring the role of sphingolipid-related genes in clinical outcomes of breast cancer.
Pei S; Zhang P; Yang L; Kang Y; Chen H; Zhao S; Dai Y; Zheng M; Xia Y; Xie H
Front Immunol; 2023; 14():1116839. PubMed ID: 36860848
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights.
Ma Y; Du J; Chen M; Gao N; Wang S; Mi Z; Wei X; Zhao J
Front Immunol; 2023; 14():1219652. PubMed ID: 37457713
[TBL] [Abstract][Full Text] [Related]
3. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M
Front Immunol; 2023; 14():1198826. PubMed ID: 38035071
[TBL] [Abstract][Full Text] [Related]
4. A pyroptosis-related gene signature predicting survival and tumor immune microenvironment in breast cancer and validation.
Gong M; Liu X; Zhao X; Wang H
BMC Cancer; 2022 Sep; 22(1):1005. PubMed ID: 36138348
[TBL] [Abstract][Full Text] [Related]
5. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
Wang Z; Liu H; Gong Y; Cheng Y
Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
[TBL] [Abstract][Full Text] [Related]
6. Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer.
Pei S; Zhang P; Chen H; Zhao S; Dai Y; Yang L; Kang Y; Zheng M; Xia Y; Xie H
Front Endocrinol (Lausanne); 2023; 14():1135297. PubMed ID: 36843602
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
8. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
10. Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer.
Jiang M; Wu X; Bao S; Wang X; Qu F; Liu Q; Huang X; Li W; Tang J; Yin Y
Front Immunol; 2022; 13():946468. PubMed ID: 35935965
[No Abstract] [Full Text] [Related]
11. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
12. Single-cell sequencing analysis related to sphingolipid metabolism guides immunotherapy and prognosis of skin cutaneous melanoma.
Ding Y; Zhao Z; Cai H; Zhou Y; Chen H; Bai Y; Liu Z; Liu S; Zhou W
Front Immunol; 2023; 14():1304466. PubMed ID: 38077400
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
14. Identification of a basement membrane-related gene signature for predicting prognosis and estimating the tumor immune microenvironment in breast cancer.
Cai J; Zhang X; Xie W; Li Z; Liu W; Liu A
Front Endocrinol (Lausanne); 2022; 13():1065530. PubMed ID: 36531485
[TBL] [Abstract][Full Text] [Related]
15. Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq.
Xu J; Qin S; Yi Y; Gao H; Liu X; Ma F; Guan M
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077333
[TBL] [Abstract][Full Text] [Related]
16. A novel immune-related prognostic index for predicting breast cancer overall survival.
Yu X; Guo J; Zhou Q; Huang W; Xu C; Long X
Breast Cancer; 2021 Mar; 28(2):434-447. PubMed ID: 33146847
[TBL] [Abstract][Full Text] [Related]
17. Identification and development of an independent immune-related genes prognostic model for breast cancer.
Chen L; Dong Y; Pan Y; Zhang Y; Liu P; Wang J; Chen C; Lu J; Yu Y; Deng R
BMC Cancer; 2021 Mar; 21(1):329. PubMed ID: 33785008
[TBL] [Abstract][Full Text] [Related]
18. Identification of CD4
Ning S; Wu J; Pan Y; Qiao K; Li L; Huang Q
Front Immunol; 2022; 13():880769. PubMed ID: 35603183
[TBL] [Abstract][Full Text] [Related]
19. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.
Ren X; Cui H; Dai L; Chang L; Liu D; Yan W; Zhao X; Kang H; Ma X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):119. PubMed ID: 38466449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
